[
  {
    "ts": null,
    "headline": "Regeneron Announces Investor Conference Presentations",
    "summary": "TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcript",
    "url": "https://finnhub.io/api/news?id=f31e25747c1253fa1be3ae9a5eee73f5064bd9b4f2164d544a110d8e83c23691",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770843900,
      "headline": "Regeneron Announces Investor Conference Presentations",
      "id": 139049600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcript",
      "url": "https://finnhub.io/api/news?id=f31e25747c1253fa1be3ae9a5eee73f5064bd9b4f2164d544a110d8e83c23691"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=33e015d47bd6920e1bc5d8ab0d4d4e586b0092b6178e6067ed3dcaad44c0dcb9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770828180,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 139064836,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=33e015d47bd6920e1bc5d8ab0d4d4e586b0092b6178e6067ed3dcaad44c0dcb9"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL",
    "summary": "NVDA, AMZN and REGN headline Zacks' top stock reports, spotlighting AI growth, cloud momentum and oncology pipeline strength.",
    "url": "https://finnhub.io/api/news?id=1fb0984c75cb8bbde44f8cba4724983005ff969b4029eadd16073c8495c9f495",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770803760,
      "headline": "The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL",
      "id": 139040999,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "NVDA, AMZN and REGN headline Zacks' top stock reports, spotlighting AI growth, cloud momentum and oncology pipeline strength.",
      "url": "https://finnhub.io/api/news?id=1fb0984c75cb8bbde44f8cba4724983005ff969b4029eadd16073c8495c9f495"
    }
  },
  {
    "ts": null,
    "headline": "Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill",
    "summary": "Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s asthma results.",
    "url": "https://finnhub.io/api/news?id=603b3095d0177beb97ccb77e34785ab3c5e7f04f443ea51515d942ad6e559ce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770802380,
      "headline": "Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill",
      "id": 139045215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s asthma results.",
      "url": "https://finnhub.io/api/news?id=603b3095d0177beb97ccb77e34785ab3c5e7f04f443ea51515d942ad6e559ce7"
    }
  }
]